KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $8000.0.

  • Travere Therapeutics' Tax Provisions rose 10952.38% to $8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5000.0, marking a year-over-year decrease of 10192.31%. This contributed to the annual value of $120000.0 for FY2024, which is 4618.83% down from last year.
  • Travere Therapeutics' Tax Provisions amounted to $8000.0 in Q3 2025, which was up 10952.38% from $20000.0 recorded in Q2 2025.
  • Travere Therapeutics' Tax Provisions' 5-year high stood at $313000.0 during Q1 2021, with a 5-year trough of -$84000.0 in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' median Tax Provisions value was $52000.0 (recorded in 2022), while the average stood at $59578.9.
  • As far as peak fluctuations go, Travere Therapeutics' Tax Provisions skyrocketed by 147500.0% in 2022, and later tumbled by 80000.0% in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Tax Provisions stood at $4000.0 in 2021, then soared by 1475.0% to $63000.0 in 2022, then rose by 7.94% to $68000.0 in 2023, then plummeted by 205.88% to -$72000.0 in 2024, then skyrocketed by 111.11% to $8000.0 in 2025.
  • Its Tax Provisions stands at $8000.0 for Q3 2025, versus $20000.0 for Q2 2025 and $39000.0 for Q1 2025.